{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T19:26:47Z","timestamp":1776540407244,"version":"3.51.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cushing\u2019s syndrome (CS) is associated with increased metabolic and cardiovascular (CV) risk factors and morbidities. Evidence-based guidelines for the management of these issues in active or remitted CS are not available, so best practice is derived from guidelines developed for the general population. We aimed to evaluate the awareness and practice variation for CV comorbidities of CS across Reference Centres (RCs) of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A dedicated online survey was distributed from June 2022 to December 2022 to Endo-ERN RCs with recognized expertise in adrenal and\/or pituitary diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>19 centres provided complete responses to the survey, accounting for an estimated pool of around one thousand chronically cared CS patients across Europe. Most ERN experts consider patients with CS at high CV risk irrespectively of remission status. Preoperative cortisol-lowering treatment was a common practice, especially for severe cases, and deemed effective in reducing CV risk by many. Most comorbidities were regularly evaluated at diagnosis and during follow-up, although a lack of provocative testing to diagnose diabetes (used only in 26% of RCs) was evidenced. A strict glycaemic control was encouraged although its target differed. On the contrary, a less stringent approach to dyslipidaemia and overweight emerged. Preferred initial compounds for patients presenting comorbidities were angiotensin converting enzyme inhibitors, metformin and statins; lifestyle changes were preferred over drugs to control weight excess after cure. Screening for asymptomatic vascular disease was performed routinely and regularly repeated during follow-up by only half of the centres. Important heterogeneity in some responses emerged, especially regarding the effect of remission or medical treatment on comorbidities and CV risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our survey highlights the awareness of ERN experts on management of metabolic and CV risk factors or disease in CS. Most of them use the current European guidelines and apply strategies for high CV risk patients, although not all these recommendations were fully followed. Since several CV risk factors seem to persist after disease remission, they should be adequately and promptly addressed. Population-specific studies are required to identify the optimal management of CV and metabolic comorbidities of CS patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-025-02663-9","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:00:42Z","timestamp":1757138442000},"page":"2657-2670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["European survey on metabolic and cardiovascular risk in Cushing syndrome"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6046-5198","authenticated-orcid":false,"given":"Alessandro","family":"Mondin","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5727","authenticated-orcid":false,"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[]},{"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[]},{"given":"Atanaska","family":"Elenkova","sequence":"additional","affiliation":[]},{"given":"Birute","family":"Zilaitiene","sequence":"additional","affiliation":[]},{"given":"Camilla","family":"Schalin-J\u00e4ntti","sequence":"additional","affiliation":[]},{"given":"Carlien","family":"De Herdt","sequence":"additional","affiliation":[]},{"given":"Christina","family":"Kanaka-Gantenbein","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-637X","authenticated-orcid":false,"given":"Dominique","family":"Maiter","sequence":"additional","affiliation":[]},{"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[]},{"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[]},{"given":"Kirstine","family":"Stochholm","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Bugalho","sequence":"additional","affiliation":[]},{"given":"Mario","family":"Detomas","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[]},{"given":"Meropi","family":"Toumba","sequence":"additional","affiliation":[]},{"given":"Roberta","family":"Giordano","sequence":"additional","affiliation":[]},{"given":"Stylianos","family":"Tsagarakis","sequence":"additional","affiliation":[]},{"given":"Susan M.","family":"Webb","sequence":"additional","affiliation":[]},{"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-3815","authenticated-orcid":false,"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"issue":"9996","key":"2663_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927. https:\/\/doi.org\/10.1016\/S0140-6736(14)61375-1","journal-title":"Lancet"},{"issue":"2","key":"2663_CR2","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.beem.2020.101380","volume":"34","author":"M Barbot","year":"2020","unstructured":"Barbot M, Zilio M, Scaroni C (2020) Cushing\u2019s syndrome: overview of clinical presentation, diagnostic tools and complications. Best Pract Res Clin Endocrinol Metab 34(2):101380. https:\/\/doi.org\/10.1016\/j.beem.2020.101380","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2663_CR3","doi-asserted-by":"publisher","unstructured":"Mondin A, Ceccato F, Voltan G et al (2023) Complications and mortality of cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. Pituitary Published Online Oct 1. https:\/\/doi.org\/10.1007\/s11102-023-01343-2","DOI":"10.1007\/s11102-023-01343-2"},{"issue":"8","key":"2663_CR4","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","volume":"107","author":"P Limumpornpetch","year":"2022","unstructured":"Limumpornpetch P, Morgan AW, Tiganescu A et al (2022) The effect of endogenous Cushing syndrome on All-cause and Cause-specific mortality. J Clin Endocrinol Metab 107(8):2377\u20132388. https:\/\/doi.org\/10.1210\/clinem\/dgac265","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2663_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2663_CR6","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1210\/jcem.84.8.5896","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A, Pivonello R, Spiezia S et al (1999) Persistence of increased cardiovascular risk in patients with cushing\u2019s disease after five years of successful cure. J Clin Endocrinol Metab 84(8):2664\u20132672. https:\/\/doi.org\/10.1210\/jcem.84.8.5896","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2663_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"Clayton RN, Jones PW, Reulen RC et al (2016) Mortality in patients with cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4(7):569\u2013576. https:\/\/doi.org\/10.1016\/S2213-8587(16)30005-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2663_CR8","doi-asserted-by":"publisher","unstructured":"Cherenko M, Appelman-Dijkstra NM, Priego Zurita AL et al (2024) Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey. Endocr Connect 13(6). https:\/\/doi.org\/10.1530\/EC-24-0046","DOI":"10.1530\/EC-24-0046"},{"issue":"2","key":"2663_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1530\/EJE-20-0197","volume":"183","author":"F de Vries","year":"2020","unstructured":"de Vries F, Bruin M, Cersosimo A et al (2020) An overview of clinical activities in Endo-ERN: the need for alignment of future network criteria. Eur J Endocrinol 183(2):141\u2013148. https:\/\/doi.org\/10.1530\/EJE-20-0197","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2663_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ando.2012.03.035","volume":"73","author":"SM Webb","year":"2012","unstructured":"Webb SM, Santos A, Valassi E (2012) The value of a European registry for pituitary adenomas: the example of cushing\u2019s syndrome registry. Ann Endocrinol (Paris) 73(2):83\u201389. https:\/\/doi.org\/10.1016\/j.ando.2012.03.035","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2663_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"issue":"12","key":"2663_CR12","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 65(12):1925\u20131966. https:\/\/doi.org\/10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"issue":"39","key":"2663_CR13","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"issue":"1","key":"2663_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-022-01575-9","volume":"21","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferovi\u0107 PM, Wanner C (2022) Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol 21(1):144. https:\/\/doi.org\/10.1186\/s12933-022-01575-9","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2663_CR15","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M et al (2023) 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension. J Hypertens 41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480","journal-title":"J Hypertens"},{"issue":"38","key":"2663_CR16","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM et al (2024) 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178","journal-title":"Eur Heart J"},{"issue":"2","key":"2663_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH et al (2015) Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(2):342\u2013362. https:\/\/doi.org\/10.1210\/jc.2014-3415","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2663_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-2265.2011.04124.x","volume":"75","author":"MJ Bolland","year":"2011","unstructured":"Bolland MJ, Holdaway IM, Berkeley JE et al (2011) Mortality and morbidity in cushing\u2019s syndrome in new Zealand. Clin Endocrinol (Oxf) 75(4):436\u2013442. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04124.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2663_CR19","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.1210\/jc.2003-032180","volume":"89","author":"GD Hammer","year":"2004","unstructured":"Hammer GD, Tyrrell JB, Lamborn KR et al (2004) Transsphenoidal microsurgery for cushing\u2019s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348\u20136357. https:\/\/doi.org\/10.1210\/jc.2003-032180","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2663_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-17-0997","volume":"178","author":"E Valassi","year":"2018","unstructured":"Valassi E, Franz H, Brue T et al (2018) Preoperative medical treatment in cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 178(4):399\u2013409. https:\/\/doi.org\/10.1530\/EJE-17-0997","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2663_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/BF03347534","volume":"27","author":"S Zacharieva","year":"2004","unstructured":"Zacharieva S, Orbetzova M, Stoynev A et al (2004) Circadian blood pressure profile in patients with cushing\u2019s syndrome before and after treatment. J Endocrinol Invest 27(10):924\u2013930. https:\/\/doi.org\/10.1007\/BF03347534","journal-title":"J Endocrinol Invest"},{"key":"2663_CR22","doi-asserted-by":"publisher","unstructured":"Barbot M, Ceccato F, Scaroni C (2019) The pathophysiology and treatment of hypertension in patients with cushing\u2019s syndrome. Front Endocrinol (Lausanne) 10. https:\/\/doi.org\/10.3389\/fendo.2019.00321","DOI":"10.3389\/fendo.2019.00321"},{"issue":"11","key":"2663_CR23","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/HJH.0000000000003252","volume":"40","author":"F Fallo","year":"2022","unstructured":"Fallo F, Di Dalmazi G, Beuschlein F et al (2022) Diagnosis and management of hypertension in patients with cushing\u2019s syndrome: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens 40(11):2085\u20132101. https:\/\/doi.org\/10.1097\/HJH.0000000000003252","journal-title":"J Hypertens"},{"issue":"33","key":"2663_CR24","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J 39(33):3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"2663_CR25","doi-asserted-by":"publisher","unstructured":"Barbot M, Ceccato F, Scaroni C (2018) Diabetes mellitus secondary to cushing\u2019s disease. Front Endocrinol (Lausanne) 9. https:\/\/doi.org\/10.3389\/fendo.2018.00284","DOI":"10.3389\/fendo.2018.00284"},{"key":"2663_CR26","doi-asserted-by":"publisher","unstructured":"Guarnotta V, Emanuele F, Salzillo R et al (2023) Practical therapeutic approach in the management of diabetes mellitus secondary to cushing\u2019s syndrome, acromegaly and neuroendocrine tumours. Front Endocrinol (Lausanne) 14. https:\/\/doi.org\/10.3389\/fendo.2023.1248985","DOI":"10.3389\/fendo.2023.1248985"},{"issue":"25","key":"2663_CR27","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"Intensive Diabetes Treatment","year":"2005","unstructured":"Intensive Diabetes Treatment (2005) And cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643\u20132653. https:\/\/doi.org\/10.1056\/NEJMoa052187","journal-title":"N Engl J Med"},{"issue":"15","key":"2663_CR28","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-Year Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"issue":"24","key":"2663_CR29","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"Intensive Blood Glucose Control","year":"2008","unstructured":"Intensive Blood Glucose Control (2008) Vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987","journal-title":"N Engl J Med"},{"issue":"2","key":"2663_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa0808431","journal-title":"N Engl J Med"},{"issue":"24","key":"2663_CR31","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","year":"2008","unstructured":"Effects of Intensive Glucose Lowering in Type 2 Diabetes (2008) N Engl J Med 358(24):2545\u20132559. https:\/\/doi.org\/10.1056\/NEJMoa0802743","journal-title":"N Engl J Med"},{"issue":"1","key":"2663_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mcna.2012.01.009","volume":"96","author":"SS Martin","year":"2012","unstructured":"Martin SS, Blumenthal RS, Miller MLDL, Cholesterol (2012) The lower the better. Med Clin North Am 96(1):13\u201326. https:\/\/doi.org\/10.1016\/j.mcna.2012.01.009","journal-title":"Med Clin North Am"},{"key":"2663_CR33","doi-asserted-by":"publisher","first-page":"101882","DOI":"10.1016\/j.eclinm.2023.101882","volume":"58","author":"M Chakhtoura","year":"2023","unstructured":"Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS (2023) Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine 58:101882. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101882","journal-title":"EClinicalMedicine"},{"key":"2663_CR34","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. New Engl J Medicine Published Online November 11. https:\/\/doi.org\/10.1056\/NEJMoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"2663_CR35","doi-asserted-by":"publisher","unstructured":"Kamarullah W, Pranata R, Wiramihardja S, Tiksnadi BB (2024) Role of incretin mimetics in cardiovascular outcomes and other classical cardiovascular risk factors beyond obesity and diabetes mellitus in nondiabetic adults with obesity: a Meta-analysis of randomized controlled trials. American J Cardiovasc Drugs Published Online November 30. https:\/\/doi.org\/10.1007\/s40256-024-00695-9","DOI":"10.1007\/s40256-024-00695-9"},{"key":"2663_CR36","doi-asserted-by":"publisher","unstructured":"Pattipati M, Gudavalli G (2022) Association Between Cushing\u2019s Syndrome and Sleep Apnea: Results From the National Inpatient Sample. Cureus. Published online February 9. https:\/\/doi.org\/10.7759\/cureus.22044","DOI":"10.7759\/cureus.22044"},{"key":"2663_CR37","doi-asserted-by":"publisher","unstructured":"Naylor R, Rantner B, Ancetti S et al (eds) (2023) \u2019s Choice\u2013 European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery.;65(1):7-111. https:\/\/doi.org\/10.1016\/j.ejvs.2022.04.011","DOI":"10.1016\/j.ejvs.2022.04.011"},{"issue":"11","key":"2663_CR38","doi-asserted-by":"publisher","first-page":"E2144","DOI":"10.1210\/jc.2014-1783","volume":"99","author":"P Kamenick\u00fd","year":"2014","unstructured":"Kamenick\u00fd P, Redheuil A, Roux C et al (2014) Cardiac structure and function in cushing\u2019s syndrome: A cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 99(11):E2144\u2013E2153. https:\/\/doi.org\/10.1210\/jc.2014-1783","journal-title":"J Clin Endocrinol Metab"},{"issue":"38","key":"2663_CR39","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 44(38):3720\u20133826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"issue":"3","key":"2663_CR40","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873221100032","volume":"7","author":"J Dawson","year":"2022","unstructured":"Dawson J, B\u00e9jot Y, Christensen LM et al (2022) European stroke organisation (ESO) guideline on Pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J 7(3):I\u2013XLI. https:\/\/doi.org\/10.1177\/23969873221100032","journal-title":"Eur Stroke J"},{"issue":"2","key":"2663_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0621","volume":"162","author":"AM Pereira","year":"2010","unstructured":"Pereira AM, Delgado V, Romijn JA, Smit JWA, Bax JJ, Feelders RA (2010) Cardiac dysfunction is reversed upon successful treatment of cushing\u2019s syndrome. Eur J Endocrinol 162(2):331\u2013340. https:\/\/doi.org\/10.1530\/EJE-09-0621","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2663_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0895-7061(95)00299-5","volume":"9","author":"F Fallo","year":"1996","unstructured":"Fallo F, Sonino N, Barzon L et al (1996) Effect of surgical treatment on hypertension in cushing\u2019s syndrome. Am J Hypertens 9(1):77\u201380. https:\/\/doi.org\/10.1016\/0895-7061(95)00299-5","journal-title":"Am J Hypertens"},{"issue":"6","key":"2663_CR43","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2002-021558","volume":"88","author":"A Faggiano","year":"2003","unstructured":"Faggiano A, Pivonello R, Spiezia S et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with cushing\u2019s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88(6):2527\u20132533. https:\/\/doi.org\/10.1210\/jc.2002-021558","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2663_CR44","first-page":"439","volume":"67","author":"RM G\u00f3mez","year":"2007","unstructured":"G\u00f3mez RM, Albiger NME, D\u00edaz AG, Moncet D, Pitoia FA, Bruno OD (2007) Effect of hypercortisolism control on high blood pressure in cushing\u2019s syndrome. Med (B Aires) 67(5):439\u2013444","journal-title":"Med (B Aires)"},{"issue":"3","key":"2663_CR45","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2265.2011.04055.x","volume":"75","author":"R Giordano","year":"2011","unstructured":"Giordano R, Picu A, Marinazzo E et al (2011) Metabolic and cardiovascular outcomes in patients with cushing\u2019s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 75(3):354\u2013360. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04055.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2663_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","volume":"64","author":"MH Schernthaner-Reiter","year":"2019","unstructured":"Schernthaner-Reiter MH, Siess C, Gessl A et al (2019) Factors predicting long-term comorbidities in patients with cushing\u2019s syndrome in remission. Endocrine 64(1):157\u2013168. https:\/\/doi.org\/10.1007\/s12020-018-1819-6","journal-title":"Endocrine"},{"issue":"2","key":"2663_CR47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/cen.14129","volume":"92","author":"S Jha","year":"2020","unstructured":"Jha S, Sinaii N, McGlotten RN, Nieman LK (2020) Remission of hypertension after surgical cure of cushing\u2019s syndrome. Clin Endocrinol (Oxf) 92(2):124\u2013130. https:\/\/doi.org\/10.1111\/cen.14129","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2663_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2478\/enr-2023-0017","volume":"57","author":"M Chihaoui","year":"2023","unstructured":"Chihaoui M, Oueslati I, Khessairi N et al (2023) Metabolic disorders during endogenous cushing\u2019s syndrome: prevalence, associated factors, and outcome after remission. Endocr Regul 57(1):138\u2013143. https:\/\/doi.org\/10.2478\/enr-2023-0017","journal-title":"Endocr Regul"},{"key":"2663_CR49","doi-asserted-by":"publisher","unstructured":"Zhou H, Yin Y, Zhang P et al (2024) Long-term outcome of unilateral adrenalectomy for primary bilateral macronodular adrenal hyperplasia. Endocrine Published Online Oct 9. https:\/\/doi.org\/10.1007\/s12020-024-04030-9","DOI":"10.1007\/s12020-024-04030-9"},{"issue":"34","key":"2663_CR50","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"key":"2663_CR51","doi-asserted-by":"publisher","unstructured":"Tizianel I, Lizzul L, Mondin A et al (2025) Cardiometabolic complications after cushing\u2019s disease remission. J Endocrinol Invest Published Online March 26. https:\/\/doi.org\/10.1007\/s40618-025-02572-x","DOI":"10.1007\/s40618-025-02572-x"},{"issue":"2","key":"2663_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.numecd.2016.02.001","volume":"26","author":"MG Baroni","year":"2016","unstructured":"Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A (2016) Italian society for the study of diabetes (SID)\/Italian endocrinological society (SIE) guidelines on the treatment of hyperglycemia in cushing\u2019s syndrome and acromegaly. Nutr Metabolism Cardiovasc Dis 26(2):85\u2013102. https:\/\/doi.org\/10.1016\/j.numecd.2016.02.001","journal-title":"Nutr Metabolism Cardiovasc Dis"},{"issue":"6","key":"2663_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U et al (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary 24(6):887\u2013903. https:\/\/doi.org\/10.1007\/s11102-021-01161-4","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"2663_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000314294","volume":"92","author":"Y Greenman","year":"2010","unstructured":"Greenman Y (2010) Management of dyslipidemia in cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1):91\u201395. https:\/\/doi.org\/10.1159\/000314294","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2663_CR55","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J et al (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with cushing\u2019s disease: results from a phase\u2009<\u2009scp\u2009>\u2009iii\u2009study. Clin Endocrinol (Oxf) 81(3):408\u2013417. https:\/\/doi.org\/10.1111\/cen.12431","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2663_CR56","first-page":"26","volume":"67","author":"D Moncet","year":"2007","unstructured":"Moncet D, Morando DJ, Pitoia F, Katz SB, Rossi MA, Bruno OD (2007) Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with cushing\u2019s syndrome. Med (B Aires) 67(1):26\u201331","journal-title":"Med (B Aires)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02663-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T07:35:22Z","timestamp":1766734522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02663-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02663-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: due to the incorrect funding text in the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest that might be perceived as influencing the impartiality of the reported research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}